BioCardia (BCDA) Net Cash Flow Growth (5y) (2015 - 2026)
Powered by 
Analysis
BioCardia (BCDA) Net Cash Flow Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.36 Bn | 112.79 Mn |
| 2 | CRISPR Therapeutics AG | 5.05 Bn | 5.05 Bn | - |
| 3 | Iovance Biotherapeutics | 3.74 Bn | 3.45 Bn | 55.72 Mn |
| 4 | Legend Biotech | 3.57 Bn | 2.61 Bn | 251.50 Mn |
| 5 | uniQure | 3.00 Bn | 3.00 Bn | 5.49 Mn |
| 6 | Beam Therapeutics | 2.55 Bn | 2.55 Bn | - |
| 7 | Precigen | 2.36 Bn | 2.36 Bn | 52.17 Mn |
| 8 | Sarepta Therapeutics | 2.21 Bn | 1.42 Bn | 251.87 Mn |
| 9 | Vericel | 1.95 Bn | 1.79 Bn | 56.40 Mn |
| 10 | BioCardia | 13.18 Mn | 9.06 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 25.15% |
| Mar 31, 2026 | -78.78% |
| Dec 31, 2025 | -17.07% |
| Sep 30, 2025 | 25.92% |
| Jun 30, 2025 | 15.02% |
| Mar 31, 2025 | 13.86% |
| Dec 31, 2024 | 5.10% |
| Sep 30, 2024 | 34.19% |
| Jun 30, 2024 | 17.12% |
| Mar 31, 2024 | 42.82% |
| Dec 31, 2023 | -27.43% |
| Sep 30, 2023 | -4.17% |
| Jun 30, 2023 | 27.83% |
| Mar 31, 2023 | 3.76% |
| Dec 31, 2022 | 25.33% |
| Sep 30, 2022 | -1.78% |
| Jun 30, 2022 | 19.62% |
| Mar 31, 2022 | -4.87% |
| Dec 31, 2021 | -29.24% |
| Sep 30, 2021 | -18.48% |